Clinical effect of letrozole in treatment of idiopathic short stature in adolescent boys / 中国当代儿科杂志
Yun-Pu CUI; Xin-Li WANG.
Chinese Journal of Contemporary Pediatrics
; (12): 977-982, 2019.
Artículo
en Zh
| WPRIM | ID: wpr-775071
OBJECTIVE@#To evaluate the therapeutic effect and safety of letrozole in the treatment of adolescent boys with idiopathic short stature (ISS).@*METHODS@#A retrospective analysis was performed for the clinical data of 16 adolescent boys with ISS who had a bone age of ≥14 years. Among these boys, 8 were initially treated with recombinant human growth hormone (rhGH), followed by rhGH combined with letrozole during a bone age of 14-15.5 years. The other 8 boys were initially treated with rhGH combined with letrozole since their bone age was ≥14 years at diagnosis. Of the 16 boys, 16 were treated for not less than 6 months, 12 were treated for not less than 1 year, and 5 were treated for not less than 1.5 years. The increase in bone age, predicted adult height (PAH), final adult height, sex hormones, and adverse reactions after treatment were analyzed.@*RESULTS@#After 6 months, 1 year, and 1.5 years of treatment, median bone age was increased by 0 year, 0.5 year, and 0.5 year respectively, which was significantly lower than the increase in age (P0.05).@*CONCLUSIONS@#In adolescent boys with ISS and a high bone age, rhGH combined with letrozole can safely and effectively delay the increase in bone age and improve PAH and final adult height, with little adverse effect.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados